Zuoguiwan Clinical Study Of Treatment Of Liver And Kidney Of Osteoporosis

Objective:To Evaluate the clinical effect and safety resulting from Zuoguiwan when used to treat osteoporosis with liver-kidney-yin deficiency syndrome so as to find a safe, effective and reasonable way for the treatment of such disease.Methods:Through comparative study between Chinese and Western medicine, and in accordance with inclusion and exclusion criteria of cases,38 cases with liver-kidney-yin deficiency syndrome were selected from 97 patients with osteoporosis treated during March to September in 2008. And based on open, fair, just, and random principle, such selected cases were divided into treatment group and comparative group wherein 12 cases from the former took Zuoguiwan, while 12 cases from the latter took Alfacalcidol Soft Capsule. Both groups underwent 3 months for a course of treatment. All selected patients had to receive three months of systemic therapy, regular follow-up visit and review. After the end of treatment, evaluation scores and efficacy evaluation on clinical symptoms were given to the groups. Then review of bone density, liver and kidney function were given. Finally, the SPSS 13.0 statistical software was applied to analyse and compare the effects from these two treatment methods for the clinical sdyndromes such as bone pain of osteoporosis with liver-kidney-yin deficiency while the effects for improving bone density from such methods were compared and their safety was evaluated.Results:Zuoguiwan possessed obvious effect on osteoporosis with liver-kidney-yin deficiency syndrome. Its total effective rate reached 84.2% while such rate of Alfacalcidol Soft Capsule was 68.4%. There was significant difference (P<0.05) between the effects from both groups when compared:the effect of Zuoguiwan was obviously superior to Alfacalcidol Soft Capsule.When the changes in scores of bone pain of both groups were compared, significant difference (P<0.01) was found in before- and-after-treatment. The decreased difference of the treatment group compared with the comparative group was significant (P<0.01) that is, the improvement for bone pain of Zuoguiwan was significantly better than the one in the comparative group. When the changes in bone density before and after treatment of both groups were compared, all 19 cases in the treatment group were found to experience obvious increased bone density after taking Zuoguiwan:there was significant difference(P<0.01) in before-treatment bone density compared with after-treatment one. Thereby, Zuoguiwan could significantly increase bone density in osteoporosis patients. After treatment,all the patients experienced examinations for liver and kidney function, and no obvious abnormalities were found.Conclusion:Clinical observation found that both drugs took obvious effects on osteoporosis with liver-kidney-yin deficiency syndrome. Compared with pre-treatment, clinical symptoms and bone density improved significantly in both groups, and the treatment group experienced obviously better effect than the comparative group. As far drug safety is concerned, there was no difference between the two groups after treatment. All the patients received checks for liver and kidney function, and no significant liver and kidney dysfunction was found through review after drugs were taken.